Pancreatic Cancer Research

ResearcherUniversity of FoggiaActive in the last 2 years

Guido Giordano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9310-1075; OpenAlex author ID A5014449716. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 17

  1. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. First author DOI 10.1093/oncolo/oyag085↗
  2. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  3. Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life. First author DOI 10.1016/j.dld.2024.06.025↗
  4. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  5. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  6. Altered centriolar cohesion by CEP250 and appendages impact outcome of patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.06.010↗
  7. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  8. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  9. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  10. Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad101↗
  11. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  12. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  13. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Co-author DOI 10.3390/curroncol28030164↗
  14. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Co-author DOI 10.1177/1758835919850367↗
  15. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Last author DOI 10.1155/2018/7530619↗
  16. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. Co-author DOI 10.3748/wjg.v23.i32.5875↗
  17. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. Co-author DOI 10.1186/s12885-016-2671-9↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giampaolo Tortora · 9 shared papers, 2021–2026 · strength 1.21
  2. Elisa Giommoni · 8 shared papers, 2021–2026 · strength 1.11
  3. Letizia Procaccio · 7 shared papers, 2023–2026 · strength 1.10
  4. Marina Macchini · 7 shared papers, 2021–2025 · strength 0.95
  5. Giulia Orsi · 7 shared papers, 2021–2025 · strength 0.95
  6. Michele Reni · 7 shared papers, 2021–2025 · strength 0.95
  7. Stefano Cascinu · 7 shared papers, 2021–2025 · strength 0.95
  8. Michèle Milella · 7 shared papers, 2021–2025 · strength 0.88
  9. Matteo Landriscina · 5 shared papers, 2023–2026 · strength 0.86
  10. Monica Niger · 6 shared papers, 2021–2026 · strength 0.80
  11. Ilario Giovanni Rapposelli · 6 shared papers, 2021–2025 · strength 0.80
  12. Sara Lonardi · 5 shared papers, 2023–2026 · strength 0.76
  13. Mario Scartozzi · 5 shared papers, 2021–2026 · strength 0.70
  14. Lisa Salvatore · 5 shared papers, 2021–2025 · strength 0.66
  15. Mariacristina Di Marco · 5 shared papers, 2021–2026 · strength 0.66
  16. Francesca Bergamo · 4 shared papers, 2023–2026 · strength 0.64
  17. Umberto Peretti · 5 shared papers, 2021–2025 · strength 0.64
  18. Enrico Vasile · 4 shared papers, 2023–2026 · strength 0.63
  19. Ferdinando De Vita · 5 shared papers, 2016–2026 · strength 0.62
  20. Davide Melisi · 4 shared papers, 2021–2026 · strength 0.57
  21. Silvia Bozzarelli · 4 shared papers, 2021–2025 · strength 0.51
  22. Alberto Zaniboni · 3 shared papers, 2023–2026 · strength 0.48
  23. Maria Grazia Rodriquenz · 4 shared papers, 2021–2025 · strength 0.46
  24. Vanja Vaccaro · 3 shared papers, 2021–2024 · strength 0.39
  25. Andrea Spallanzani · 3 shared papers, 2021–2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.